BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 23877355)

  • 1. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.
    Rider LG; Shah M; Mamyrova G; Huber AM; Rice MM; Targoff IN; Miller FW;
    Medicine (Baltimore); 2013 Jul; 92(4):223-243. PubMed ID: 23877355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.
    Shah M; Mamyrova G; Targoff IN; Huber AM; Malley JD; Rice MM; Miller FW; Rider LG;
    Medicine (Baltimore); 2013 Jan; 92(1):25-41. PubMed ID: 23263716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies.
    Perron MM; Vasquez-Canizares N; Tarshish G; Wahezi DM
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):92. PubMed ID: 34118936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.
    Rider LG; Nistala K
    J Intern Med; 2016 Jul; 280(1):24-38. PubMed ID: 27028907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
    Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
    Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
    Love LA; Leff RL; Fraser DD; Targoff IN; Dalakas M; Plotz PH; Miller FW
    Medicine (Baltimore); 1991 Nov; 70(6):360-74. PubMed ID: 1659647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling.
    Melki I; Devilliers H; Gitiaux C; Bondet V; Duffy D; Charuel JL; Miyara M; Bokov P; Kheniche A; Kwon T; Authier FJ; Allenbach Y; Belot A; Bodemer C; Bourrat E; Dumaine C; Fabien N; Faye A; Frémond ML; Hadchouel A; Kitabayashi N; Lepelley A; Martin-Niclos MJ; Mudumba S; Musset L; Quartier P; Rice GI; Seabra L; Uettwiller F; Uggenti C; Viel S; Rodero MP; Crow YJ; Bader-Meunier B
    Rheumatology (Oxford); 2020 Aug; 59(8):1927-1937. PubMed ID: 31755959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.
    Habers GE; Huber AM; Mamyrova G; Targoff IN; O'Hanlon TP; Adams S; Pandey JP; Boonacker C; van Brussel M; Miller FW; van Royen-Kerkhof A; Rider LG;
    Arthritis Rheumatol; 2016 Mar; 68(3):761-8. PubMed ID: 26474155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
    Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
    Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
    Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
    Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes.
    Scalabrini JC; Schiffenbauer AI; Farhadi PN; Volochayev R; Bayat N; Jansen A; Targoff IN; Miller FW; Rider LG
    Pediatr Rheumatol Online J; 2022 Apr; 20(1):28. PubMed ID: 35414090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myositis-specific autoantibodies].
    Fujimoto M
    Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical features of juvenile dermatomyositis: A single-centre inception cohort.
    Cancarini P; Nozawa T; Whitney K; Bell-Peter A; Marcuz JA; Taddio A; Guo J; Dover S; Feldman BM
    Semin Arthritis Rheum; 2022 Dec; 57():152104. PubMed ID: 36183479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis.
    Gupta L; Naveen R; Gaur P; Agarwal V; Aggarwal R
    Semin Arthritis Rheum; 2021 Feb; 51(1):113-120. PubMed ID: 33360322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.
    Troyanov Y; Targoff IN; Payette MP; Raynauld JP; Chartier S; Goulet JR; Bourré-Tessier J; Rich E; Grodzicky T; Fritzler MJ; Joyal F; Koenig M; Senécal JL
    Medicine (Baltimore); 2014 Nov; 93(24):318-332. PubMed ID: 25500701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
    Mariampillai K; Granger B; Amelin D; Guiguet M; Hachulla E; Maurier F; Meyer A; Tohmé A; Charuel JL; Musset L; Allenbach Y; Benveniste O
    JAMA Neurol; 2018 Dec; 75(12):1528-1537. PubMed ID: 30208379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.
    Zampeli E; Venetsanopoulou A; Argyropoulou OD; Mavragani CP; Tektonidou MG; Vlachoyiannopoulos PG; Tzioufas AG; Skopouli FN; Moutsopoulos HM
    Clin Rheumatol; 2019 Jan; 38(1):125-132. PubMed ID: 30145635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
    Yamasaki Y; Kobayashi N; Akioka S; Yamazaki K; Takezaki S; Nakaseko H; Ohara A; Nishimura K; Nishida Y; Sato S; Kishi T; Hashimoto M; Mori M; Okazaki Y; Kuwana M; Ohta A
    Rheumatology (Oxford); 2021 Oct; 60(10):4821-4831. PubMed ID: 33576399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With Myositis-Specific Autoantibodies.
    Casal-Dominguez M; Pinal-Fernandez I; Pak K; Huang W; Selva-O'Callaghan A; Albayda J; Casciola-Rosen L; Paik JJ; Tiniakou E; Mecoli CA; Lloyd TE; Danoff SK; Christopher-Stine L; Mammen AL
    Arthritis Rheumatol; 2022 Mar; 74(3):508-517. PubMed ID: 34480833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
    Leung AKC; Lam JM; Alobaida S; Leong KF; Wong AHC
    Curr Pediatr Rev; 2021; 17(4):273-287. PubMed ID: 33902423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.